Life Technologies and Sino Biological Inc. Sign Strategic Partnership Agreement for Global Distribution and Product Development
BEIJING, Aug. 30, 2012 /PRNewswire/ — Life Technologies Corporation (NASDAQ:LIFE), a U.S.-based global biotechnology leader, and Sino Biological Inc., a leading Chinese biotech company, today announced a partnership for worldwide product distribution and product development. Life Technologies will distribute Sino Biological’s extensive portfolio of recombinant proteins, antibodies and Elisa kits utilizing its global distribution channels. The two companies will also jointly develop new products, leveraging R&D synergies to introduce innovative products more quickly. By partnering with one another, the companies are well positioned to provide proteomics products to a global customer base, and as two of the leading life science brands in China, contribute to accelerating growth of the Chinese biotech industry.
Global Distribution Channels and Innovative New Product Offerings for Dynamic Proteomics Market
“The collaboration presents a tremendous opportunity to offer a robust proteomics portfolio to meet customer needs in this highly dynamic global market,” said Gregory T. Lucier, Chairman and CEO of Life Technologies. “Through this collaboration we plan to leverage our strong brands, worldwide commercial reach and technology support with Sino Biological’s world leading technologies to develop solutions for scientists worldwide who are tackling important healthcare challenges such as cancer, diabetes and heart disease.”
“Sino Biological’s mission is to develop the best quality biological tools to assist scientists,” said Dr. Liangzhi Xie, president and CEO of Sino Biological. “Combining our state-of-the-art, disruptive technologies in recombinant protein production and antibody development with Life Technologies’ innovative product development and worldwide marketing, will allow us to bring powerful research tools to scientists solving critical puzzles in life science research and drug discovery.”
Partnership of Two Leading Life Science Brands Accelerates Growth of Chinese Science and Biotechnology
“Life Technologies is committed to supporting growth of China’s biotech industry,” said Dr. Siddhartha Kadia, Life Technologies President, Greater China. “We are delighted to partner with Sino Biological to distribute more than 6000 human-derived proteins and antibodies. These products provide high quality and exceptional value, complementing the well- recognized Novex® and Gibco® branded reagents from Life Technologies.”
Proteins and antibodies represent a fundamental tool employed by pharmaceutical researchers and academic scientists to facilitate the discovery of novel therapeutic targets in the process of drug development. Proteins and antibodies are also used to culture cells for basic research, drug discovery and production, and development of novel therapeutics such as stem cells. The agreement calls for joint development of proteomic products for additional applications including flow cytometry and imaging technologies.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today’s most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent(TM), Applied Biosystems®, Invitrogen(TM), GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: www.lifetechnologies.com.
Life Technologies operates its Greater China business with 10 sales offices in Beijing, Shanghai, Guangzhou, Chengdu, Xi’an, Shenyang, Jinan, Hong Kong and Taiwan and has approximately 1,000 employees as well as three distribution centers in Shanghai, Beijing, and Guangzhou with local inventories of thousands of products.
About Sino Biological Inc.
Sino Biological Inc. is one of the largest cDNA, recombinant protein and antibody product manufacturers and suppliers to biomedical and pharmaceutical research in the world. With cutting-edge protein production and second-generation rabbit monoclonal antibody technologies, Sino Biological has developed capabilities and capacities to produce over 1000 new recombinant protein bulks per year in house. It has now commercialized more than 10,000 products, including 3000 recombinant protein and 3000 antibody products, and is quickly becoming the leading global biological solution specialist, offering a comprehensive set of value-added and cost-effective premium quality solutions (CRO services and reagents) to accelerate life science research and biological product development worldwide. Sino Biological is determined to develop and bring only the best quality research tools to scientists worldwide at affordable cost. To learn more about Sino Biological, please visit our website: http://www.sinobiological.com.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies, Greater China
Sino Biological Inc.
SOURCE Life Technologies Corporation